Float Short %

5.97

Margin Of Safety %

-25

Put/Call OI Ratio

0.71

EPS Next Q Diff

EPS Last/This Y

0.55

EPS This/Next Y

0.31

Price

9.85

Target Price

15.9

Analyst Recom

1.2

Performance Q

24.84

Relative Volume

0.62

Beta

0.46

Ticker: FOLD

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	FOLD	9.01	0.63	0.49	28395
2025-11-11	FOLD	9.32	0.63	1.29	28493
2025-11-12	FOLD	9.42	0.66	0.00	29160
2025-11-13	FOLD	9.39	0.66	0.02	29172
2025-11-14	FOLD	9.48	0.66	0.03	29226
2025-11-17	FOLD	9.43	0.65	4.67	29277
2025-11-18	FOLD	9.6	0.66	0.01	29401
2025-11-19	FOLD	9.73	0.66	0.36	29556
2025-11-20	FOLD	9.45	0.76	8.75	30694
2025-11-21	FOLD	9.56	0.73	4.07	31056
2025-11-24	FOLD	9.89	0.71	0.03	26131
2025-11-25	FOLD	9.86	0.72	0.01	26120
2025-11-26	FOLD	10.02	0.72	0.43	26105
2025-12-01	FOLD	9.8	0.72	0.37	26158
2025-12-02	FOLD	9.74	0.72	0.00	26156
2025-12-03	FOLD	9.79	0.72	0.00	26168
2025-12-04	FOLD	9.95	0.71	0.00	26184
2025-12-05	FOLD	9.91	0.71	0.00	26259
2025-12-08	FOLD	9.85	0.71	0.00	26207
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	FOLD	9.00	81.0	159.4	0.35
2025-11-11	FOLD	9.32	44.4	163.5	0.36
2025-11-12	FOLD	9.43	44.4	158.8	0.36
2025-11-13	FOLD	9.39	44.4	155.9	0.36
2025-11-14	FOLD	9.49	44.4	158.9	0.36
2025-11-17	FOLD	9.43	44.4	155.4	0.36
2025-11-18	FOLD	9.59	44.4	159.9	0.36
2025-11-19	FOLD	9.73	44.4	159.4	0.36
2025-11-20	FOLD	9.45	75.9	151.0	0.37
2025-11-21	FOLD	9.56	77.8	159.0	0.37
2025-11-24	FOLD	9.89	77.8	163.3	0.37
2025-11-25	FOLD	9.87	77.8	156.1	0.37
2025-11-26	FOLD	10.02	77.8	159.4	0.37
2025-12-01	FOLD	9.80	77.8	153.9	0.37
2025-12-02	FOLD	9.73	77.8	155.1	0.37
2025-12-03	FOLD	9.78	77.8	157.6	0.37
2025-12-04	FOLD	9.96	77.8	160.2	0.37
2025-12-05	FOLD	9.90	77.8	155.5	0.37
2025-12-08	FOLD	9.85	77.8	-	0.37
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	FOLD	-0.37	1.08	6.28
2025-11-11	FOLD	-0.37	1.08	6.28
2025-11-12	FOLD	-0.37	1.08	5.65
2025-11-13	FOLD	-0.37	1.08	5.65
2025-11-14	FOLD	-0.37	1.08	5.65
2025-11-17	FOLD	-0.37	4.80	5.65
2025-11-18	FOLD	-0.37	4.80	5.65
2025-11-19	FOLD	-0.37	4.80	5.65
2025-11-20	FOLD	-0.37	4.80	5.65
2025-11-21	FOLD	-0.37	4.80	5.65
2025-11-24	FOLD	-0.37	-1.23	5.64
2025-11-25	FOLD	-0.41	-1.23	5.64
2025-11-26	FOLD	-0.41	-1.23	5.97
2025-12-01	FOLD	-3.67	-1.19	5.97
2025-12-02	FOLD	-3.67	-1.19	5.97
2025-12-03	FOLD	-3.59	-1.19	5.97
2025-12-04	FOLD	-3.80	-1.19	5.97
2025-12-05	FOLD	-3.80	-1.19	5.97
2025-12-08	FOLD	-3.80	-0.84	5.97
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.11

Avg. EPS Est. Current Quarter

0.16

Avg. EPS Est. Next Quarter

0.11

Insider Transactions

-3.8

Institutional Transactions

-0.84

Beta

0.46

Average Sales Estimate Current Quarter

179

Average Sales Estimate Next Quarter

164

Fair Value

7.43

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

61.2

Max Drawdown 5-Year %

-77.3

Target Price

15.9

P/E

Forward P/E

36.68

PEG

P/S

5.08

P/B

13.19

P/Free Cash Flow

313.63

EPS

-0.04

Average EPS Est. Cur. Y

0.37

EPS Next Y. (Est.)

0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2.35

Relative Volume

0.62

Return on Equity vs Sector %

-33

Return on Equity vs Industry %

-18.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

Amicus Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 499

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

stock quote shares FOLD – Amicus Therapeutics, Inc. Stock Price stock today

news today FOLD – Amicus Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch FOLD – Amicus Therapeutics, Inc. yahoo finance google finance

stock history FOLD – Amicus Therapeutics, Inc. invest stock market

stock prices FOLD premarket after hours

ticker FOLD fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: FOLD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y